Design, Synthesis and Biological Evaluation of Novel Pleuromutilin Derivatives Containing 6-Chloro-1-R-1H-pyrazolo[3,4-d]pyrimidine-4-amino Side Chain

Jun Wang,Yu-Han Hu,Ke-Xin Zhou,Wei Wang,Fei Li,Ke Li,Guang-Yu Zhang,You-Zhi Tang

DOI: https://doi.org/10.3390/molecules28093975

IF: 4.6

2023-05-08

Molecules

Abstract:Two series of pleuromutilin derivatives were designed and synthesized as inhibitors against Staphylococcus aureus (S. aureus). 6-chloro-4-amino-1-R-1H-pyrazolo[3,4-d]pyrimidine or 4-(6-chloro-1-R-1H-pyrazolo[3,4-d]pyrimidine-4-yl)amino-phenylthiol were connected to pleuromutilin. A diverse array of substituents was introduced at the N-1 position of the pyrazole ring. The in vitro antibacterial activities of these semisynthetic derivatives were evaluated against two standard strains, Methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300, Staphylococcus aureus (S. aureus), ATCC 29213 and two clinical S. aureus strains (144, AD3) using the broth dilution method. Compounds 12c, 19c and 22c (MIC = 0.25 μg/mL) manifested good in vitro antibacterial ability against MRSA which was similar to that of tiamulin (MIC = 0.5 μg/mL). Among them, compound 22c killed MRSA in a time-dependent manner and performed faster bactericidal kinetics than tiamulin in time–kill curves. In addition, compound 22c exhibited longer PAE than tiamulin, and showed no significant inhibition on the cell viability of RAW 264.7, Caco-2 and 16-HBE cells at high doses (≤8 μg/mL). The neutropenic murine thigh infection model study revealed that compound 22c displayed more effective in vivo bactericidal activity than tiamulin in reducing MRSA load. The molecular docking studies indicated that compound 22c was successfully localized inside the binding pocket of 50S ribosomal, and four hydrogen bonds played important roles in the binding of them.

chemistry, multidisciplinary,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop new antibiotics against methicillin - resistant Staphylococcus aureus (MRSA). Specifically, the researchers designed and synthesized pleuromutilin derivatives containing 6 - chloro - 1 - R - 1H - pyrazolo[3,4 - d]pyrimidin - 4 - amino side chains and evaluated the in vitro and in vivo antibacterial activities of these compounds against MRSA. In addition, the mechanism of these derivatives binding to the 50S ribosome was explored through molecular docking studies, in the hope of finding new compounds with stronger antibacterial effects, especially for drug - resistant bacterial infections. The paper mentions that with the increase of drug - resistant bacteria, especially the wide spread of MRSA, there is an urgent need for new antibacterial drugs to meet this public health challenge. Pleuromutilin and its derivatives have become ideal candidates for the development of new antibacterial drugs because of their unique antibacterial mechanism (inhibiting bacterial protein synthesis by interacting with the 50S ribosome). Therefore, this study aims to improve its efficacy against MRSA by chemically modifying pleuromutilin, especially by introducing specific azacyclic structures, such as 6 - chloro - 1 - R - 1H - pyrazolo[3,4 - d]pyrimidine.

Design, Synthesis and Biological Evaluation of Novel Pleuromutilin Derivatives Containing 6-Chloro-1-R-1H-pyrazolo[3,4-d]pyrimidine-4-amino Side Chain

Synthesis and antibacterial activities of novel pleuromutilin derivatives with a substituted pyrimidine moiety

Design, synthesis and biological evaluation of novel pleuromutilin derivatives possessing 4-aminothiophenol linker as promising antibacterial agents

Design, synthesis and biological activities of novel pleuromutilin derivatives with a substituted triazole moiety as potent antibacterial agents

Design, Synthesis and Antibacterial Evaluation of Pleuromutilin Derivatives

Design, synthesis and biological evaluation of novel pleuromutilin derivatives containing piperazine and 1,2,3-triazole linker

Design, synthesis, and antibacterial activity of pleuromutilin derivatives

Novel pleuromutilin derivatives with substituted 6-methylpyrimidine: Design, synthesis and antibacterial evaluation

Design, synthesis and biological evaluation of novel pleuromutilin derivatives as potent anti-MRSA agents targeting the 50S ribosome

Discovery of novel pleuromutilin derivatives as potent antibacterial agents

Design, synthesis, in vitro and in vivo evaluation against MRSA and molecular docking studies of novel pleuromutilin derivatives bearing 1, 3, 4-oxadiazole linker

Antibacterial activity evaluation of pleuromutilin derivatives with 4(3 H )-quinazolinone scaffold against methicillin-resistant Staphylococcus aureus

Design, synthesis and biological evaluation of pleuromutilin-Schiff base hybrids as potent anti-MRSA agents in vitro and in vivo

Semisynthetic pleuromutilin antimicrobials with therapeutic potential against methicillin-resistant Staphylococcus aureus by targeting 50S ribosomal subunit

Novel Aminopyrimidinyl Benzimidazoles As Potentially Antimicrobial Agents: Design, Synthesis and Biological Evaluation

Antibiotic resistance and drug modification: Synthesis, characterization and bioactivity of newly modified potent pleuromutilin derivatives with a substituted piperazine moiety

Discovery of Novel Pleuromutilin Derivatives as Potent Antibacterial Agents for the Treatment of MRSA Infection

Synthesis and Biological Activities of Oxazolidinone Pleuromutilin Derivatives as a Potent Anti-MRSA Agent

Synthesis and biological evaluation of novel pleuromutilin derivatives with nitrogen-containing heterocycles as antibacterial agents

In Vitro and In Vivo Antibacterial Activity, Toxicity and Resistance Analysis of Pleuromutilin Derivative Z33 against Methicillin-Resistant Staphylococcus aureus

Synthesis and Antibacterial Activity of Alkylamine-Linked Pleuromutilin Derivatives